Status:
COMPLETED
Irinotecan Hydrochloride Liposome Injection (LY01610) For Advanced Solid Tumors
Lead Sponsor:
Luye Pharma Group Ltd.
Conditions:
Advanced Solid Tumor
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
Brief Summary
This is a Phase I, open-label, non-randomized, dose-escalation study to evaluate the safety and tolerability, the maximum tolerated dose (MTD) and the dose limited toxicity(DLT) of LY01610 monotherapy...
Detailed Description
This study will be conducted in two stages: In the first stage, ascending doses of LY01610 will be administered as monotherapy in participants with solid tumors. The starting dose was 30 mg/m2 and the...
Eligibility Criteria
Inclusion
- Male or female patients aged 18 to 70 years (18 years and 70 years are inclusive).
- Histologically or cytologically confirmed solid tumor for which failed or could not •tolerate standard treatment, or standard effective treatment does not exist.
- The patient should have at least one measurable lesion as the target lesion (according to RECIST 1.1 criteria).
- The predictable survival duration ≥ 3 months.
- The Eastern Cooperative Oncology Group (ECOG) performance status score \< 2 point.
- Laboratory results during screening:
- Hematology: Absolute neutrophil count ≥ 1.5× 109/L, platelet count≥ 100× 109/L and hemoglobin≥ 90 g/L;
- Liver function: Total bilirubin（TBIL）≤ 1.5×upper limit of normal (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5×ULN for the subjects without liver metastasis; ALT and AST≤ 5×ULN for the subjects with liver metastasis;
- Kidney function: Serum creatinine ≤ 1.5 ×ULN or creatinine clearance rate ≥ 50 mL/min(Cockcroft-Gault formula);
- The subject has voluntarily signed the written informed consent form (ICF) and can comply with the study protocol;
- The female subjects of childbearing age and male subjects with fertility potential female partner agree to take reliable contraceptive measures (such as abstinence, sterilizing operation, contraceptives, injection of the contraceptive drug •medroxyprogesterone acetate or subdermal implant of contraceptives) during the study period and within 6 months after infusion of the study drugs.
Exclusion
- Patients with brain malignant tumor, lymphoma or other malignant blood diseases;
- The subjects with symptomatic brain metastasis;
- Other malignant tumors within 5 years prior to screening (except for stage Ib or lower cervical cancer, non-invasive basal cells or squamous cell skin cancer that have been cured);
- Patients with uncontrollable ascites, pleural effusion;
- Ongoing or active systemic infection need intravenous antibiotic treatment;
- Medical history of the following diseases within 6 months before screening: myocardial infarction, unstable angina, history of coronary revascularization, congestive heart failure (New York Heart Association classification ≥ grade II), severe unstable ventricular arrhythmia, serious arrhythmia which needs drug treatment;
- The patient with hepatitis B surface antigen (HBsAg) positive and the peripheral blood HBV DNA titer ≥1× 103 copies/mL or 200 IU/ml The subject is eligible to be enrolled if HBsAg is positive and peripheral blood hepatitis B virus (HBV) DNA titer \<1×103 copies/ml or 200 IU/ml and the investigator considers that the subject is at the stable stage of chronic hepatitis and the risk will not be increased for the subjects;the patient with hepatitis C virus (HCV) antibody and human immunodeficiency virus (HIV) antibody positive;
- Patients still with clinically significant electrolyte disorders that were diagnosed by the investigator before drug administration;
Key Trial Info
Start Date :
February 15 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 17 2021
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT04088604
Start Date
February 15 2019
End Date
December 17 2021
Last Update
April 26 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality, China, 100021